Abstract
Protein kinases function in key steps in several physiopathological events; therefore the development of specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and their potential uses in the treatment of GSK-3 specific pathologies.
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide design.
Current Signal Transduction Therapy
Title:Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Volume: 8 Issue: 2
Author(s): Camila Chaves Santos, Rodrigo Chaves, Ana Cristina Borges, Michelle Oliveira de Castro and Helio Miranda Costa-Junior
Affiliation:
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide design.
Abstract: Protein kinases function in key steps in several physiopathological events; therefore the development of specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and their potential uses in the treatment of GSK-3 specific pathologies.
Export Options
About this article
Cite this article as:
Santos Chaves Camila, Chaves Rodrigo, Borges Cristina Ana, de Castro Oliveira Michelle and Costa-Junior Miranda Helio, Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660007
DOI https://dx.doi.org/10.2174/15743624113086660007 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Patient-centered Medical Home as an Intervention Strategy for Diabetes Mellitus: A Systematic Review of the Literature
Current Diabetes Reviews Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Diabetes, Hyperglycemia and Accelerated Atherosclerosis: Evidence Supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Antidiabetic Oils
Current Diabetes Reviews Modifiers of Liver-Related Manifestation in the Course of NAFLD
Current Pharmaceutical Design Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes
Current Drug Discovery Technologies Novel Drug Delivery System for Cancer Management: A Review
Current Cancer Therapy Reviews Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach
Current Drug Therapy Leptin: From Animals to Humans
Current Pharmaceutical Design Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia
Current Pharmaceutical Design The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents
Current Diabetes Reviews The Concept of Titration can be Transposed to Fluid Management. But does is Change the Volumes? Randomised Trial on Pleth Variability Index During Fast-Track Colonic Surgery
Current Clinical Pharmacology Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery